Mechanism-based pharmacokinetic model for paclitaxel

Journal of Clinical Oncology

Volumn 19, Issue 20, 2001, Pages 4065-4073

  Henningsson, A ^a   Karlsson, M O ^a   Vigano L ^a   Gianni, L ^a   Verweij, J ^a   Sparreboom, A ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL SURVIVAL; CLINICAL ARTICLE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG INFUSION; FEMALE; HUMAN; MALE; MODEL; NEUTROPENIA; NEUTROPHIL; PHARMACODYNAMICS; PRIORITY JOURNAL;

EID: 0035886702     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.20.4065     Document Type: Article

References (22)

1. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients
2. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors
3. Pharmacokinetic models for the saturable distribution of paclitaxel
4. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: Clinical pharmacokinetic implications
5. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL
6. Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice
7. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
8. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
9. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression
10. Indirect-response model for the time course of leukopenia with anticancer drugs
11. Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection
12. Linearized colorimetric assay for cremophor EL: Application to pharmacokinetics after 1-hour paclitaxel infusions
13. Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay
14. Measurement of fraction unbound paclitaxel in human plasma
15. The importance of modeling interoccasion variability in population pharmacokinetic analyses
16. Xpose: An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
17. Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein
18. Extensive and saturable accumulation of paclitaxel by the human platelet
19. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
20. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo
21. Automated covariate model building within NONMEM
22. Building population pharmacokinetic-pharmacodynamic models: I. Models for covariate effects